Skip to main content
Top
Published in: Clinical Drug Investigation 5/2004

01-05-2004 | Review Article

Risk Reduction Strategies in Ischaemic Stroke

The Role of Antiplatelet Therapy

Authors: Prof. Mark J. Alberts, Richard Atkinson

Published in: Clinical Drug Investigation | Issue 5/2004

Login to get access

Abstract

Stroke is a common and serious disorder, and is a leading cause of disability and death in adults. Transient ischaemic attacks are now recognised as being common precursors of stroke, with a high risk of subsequent vascular events. The majority of strokes are ischaemic in origin, and are typically due to atherothrombosis/microatheromatosis involving a large or small cerebral blood vessel or to an embolic event. Owing to the diffuse nature of atherothrombosis, these patients are at risk of ischaemic events in other vascular beds. Options for treating patients with acute ischaemic stroke are very limited; therefore prevention is a key strategy for reducing the risk of recurrent stroke and other vascular events. Treatment of risk factors such as hypertension, diabetes mellitus, smoking and obesity is an important approach for stroke prevention. Platelets are involved in the development of thrombi and emboli, making antiplatelet therapy an important preventive strategy. Antiplatelet agents are effective in preventing recurrent ischaemic stroke and other vascular ischaemic events, such as myocardial infarction and vascular death. In some cases, anticoagulants may be effective in preventing ischaemic stroke recurrence. Carotid endarterectomy can reduce stroke risk in patients with moderate- or high-grade carotid artery stenosis. Choosing the most appropriate therapy for the individual patient is key to optimising stroke prevention.
Literature
2.
go back to reference Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002; 12: 358–70PubMed Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002; 12: 358–70PubMed
3.
go back to reference De Jong G, Kessels F, Lodder J. Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke 2002; 33: 2072–6PubMedCrossRef De Jong G, Kessels F, Lodder J. Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke 2002; 33: 2072–6PubMedCrossRef
4.
go back to reference Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack: proposal for a new definition. N Engl J Med 2002; 347: 1713–6PubMedCrossRef Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack: proposal for a new definition. N Engl J Med 2002; 347: 1713–6PubMedCrossRef
5.
go back to reference Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–6PubMedCrossRef Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–6PubMedCrossRef
6.
go back to reference Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16 Suppl. 1: 14–9PubMedCrossRef Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16 Suppl. 1: 14–9PubMedCrossRef
7.
go back to reference Droste DW, Ringelstein EB. Evaluation of progression and spread of atherothrombosis. Cerebrovasc Dis 2002; 13 Suppl. 1: 7–11PubMedCrossRef Droste DW, Ringelstein EB. Evaluation of progression and spread of atherothrombosis. Cerebrovasc Dis 2002; 13 Suppl. 1: 7–11PubMedCrossRef
8.
go back to reference Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626–34PubMedCrossRef Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626–34PubMedCrossRef
9.
go back to reference Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year survival after first-ever stroke in the Perth Community Stroke Study. Stroke 2003; 34: 1842–6PubMedCrossRef Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year survival after first-ever stroke in the Perth Community Stroke Study. Stroke 2003; 34: 1842–6PubMedCrossRef
10.
go back to reference Bauters C. Atherothrombosis: the same process for different arterial territories? Ann Cardiol Angeiol (Paris) 2002; 51: 177–80CrossRef Bauters C. Atherothrombosis: the same process for different arterial territories? Ann Cardiol Angeiol (Paris) 2002; 51: 177–80CrossRef
11.
go back to reference Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105: 181–5PubMedCrossRef Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105: 181–5PubMedCrossRef
12.
go back to reference Carr S, Farb A, Pearce WH, et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996; 23: 755–65PubMedCrossRef Carr S, Farb A, Pearce WH, et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996; 23: 755–65PubMedCrossRef
13.
14.
go back to reference Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis 1998; 8 Suppl. 5: 8–18PubMedCrossRef Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis 1998; 8 Suppl. 5: 8–18PubMedCrossRef
15.
go back to reference Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570–4PubMedCrossRef Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570–4PubMedCrossRef
16.
go back to reference DiNapoli M, Papa F, the Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763–71PubMedCrossRef DiNapoli M, Papa F, the Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763–71PubMedCrossRef
17.
go back to reference Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 2002; 325: 762–5PubMedCrossRef Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 2002; 325: 762–5PubMedCrossRef
18.
go back to reference UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044–54CrossRef UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044–54CrossRef
19.
go back to reference Lai SM, Alter M, Friday G, et al. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994; 25: 958–62PubMedCrossRef Lai SM, Alter M, Friday G, et al. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994; 25: 958–62PubMedCrossRef
20.
go back to reference Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary artery disease. Br Med Bull 1994; 50: 272–98PubMed Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary artery disease. Br Med Bull 1994; 50: 272–98PubMed
21.
go back to reference Leys D, Deplanque D, Mounier-Vehier C, et al. Stroke prevention: management of modifiable vascular risk factors. J Neurol 2002; 249: 507–17PubMedCrossRef Leys D, Deplanque D, Mounier-Vehier C, et al. Stroke prevention: management of modifiable vascular risk factors. J Neurol 2002; 249: 507–17PubMedCrossRef
22.
go back to reference Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol 2003; 91(7A): 29–39ECrossRef Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol 2003; 91(7A): 29–39ECrossRef
23.
go back to reference Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288: 1388–95PubMedCrossRef Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288: 1388–95PubMedCrossRef
24.
go back to reference Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events. Arch Neurol 2000; 57: 326–32PubMedCrossRef Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events. Arch Neurol 2000; 57: 326–32PubMedCrossRef
25.
go back to reference Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35CrossRef Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–35CrossRef
26.
go back to reference Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006–10PubMedCrossRef Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006–10PubMedCrossRef
27.
go back to reference Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke event with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001; 103: 387–92PubMedCrossRef Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke event with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001; 103: 387–92PubMedCrossRef
28.
go back to reference Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5PubMedCrossRef Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5PubMedCrossRef
29.
go back to reference Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004: 363: 757–67CrossRef Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004: 363: 757–67CrossRef
30.
go back to reference Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97 Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
31.
go back to reference Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22CrossRef Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22CrossRef
32.
go back to reference Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2002; 342: 145–53 Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2002; 342: 145–53
33.
go back to reference Sleight P, Yusuf S, Pogue J, et al. Blood pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130–1PubMedCrossRef Sleight P, Yusuf S, Pogue J, et al. Blood pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130–1PubMedCrossRef
34.
go back to reference Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41CrossRef Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41CrossRef
35.
go back to reference Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association. Stroke 2002; 33: 1934–42PubMedCrossRef Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association. Stroke 2002; 33: 1934–42PubMedCrossRef
36.
go back to reference Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86CrossRef Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86CrossRef
37.
go back to reference Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63–6PubMedCrossRef Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63–6PubMedCrossRef
38.
go back to reference Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–5PubMedCrossRef Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–5PubMedCrossRef
39.
go back to reference Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175–8PubMedCrossRef Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175–8PubMedCrossRef
40.
go back to reference Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350–5PubMedCrossRef Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350–5PubMedCrossRef
41.
go back to reference Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17PubMedCrossRef Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17PubMedCrossRef
42.
go back to reference MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–4PubMedCrossRef MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–4PubMedCrossRef
43.
go back to reference Howes LG, Kram H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drag Saf 2002; 25: 829–35CrossRef Howes LG, Kram H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drag Saf 2002; 25: 829–35CrossRef
44.
go back to reference Hankey GJ, Sudlow CLM, Dunbabin PW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779–84PubMedCrossRef Hankey GJ, Sudlow CLM, Dunbabin PW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779–84PubMedCrossRef
45.
go back to reference CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39CrossRef CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39CrossRef
46.
go back to reference Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002; 13 Suppl. 1: 22–6PubMedCrossRef Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002; 13 Suppl. 1: 22–6PubMedCrossRef
47.
go back to reference CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502CrossRef CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502CrossRef
48.
go back to reference Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20PubMedCrossRef Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20PubMedCrossRef
49.
go back to reference Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13PubMedCrossRef Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13PubMedCrossRef
50.
go back to reference Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7CrossRef Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7CrossRef
51.
go back to reference Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in Black patients: a randomized trial. JAMA 2003; 289: 3005–7CrossRef Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in Black patients: a randomized trial. JAMA 2003; 289: 3005–7CrossRef
52.
go back to reference He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280: 1930–5PubMedCrossRef He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280: 1930–5PubMedCrossRef
53.
go back to reference Serebraany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338, 191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004; 75: 40–7CrossRef Serebraany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338, 191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004; 75: 40–7CrossRef
54.
go back to reference Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183–7PubMedCrossRef Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183–7PubMedCrossRef
55.
go back to reference Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004: 35: 533–7PubMedCrossRef Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004: 35: 533–7PubMedCrossRef
56.
go back to reference Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119(1 Suppl. ): 300S–20SPubMedCrossRef Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119(1 Suppl. ): 300S–20SPubMedCrossRef
Metadata
Title
Risk Reduction Strategies in Ischaemic Stroke
The Role of Antiplatelet Therapy
Authors
Prof. Mark J. Alberts
Richard Atkinson
Publication date
01-05-2004
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 5/2004
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200424050-00001

Other articles of this Issue 5/2004

Clinical Drug Investigation 5/2004 Go to the issue